← Eichor
Study identifier: NCT05690841 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

FocaL Mass Drug Administration for Vivax Malaria Elimination

Condition: Plasmodium Vivax Malaria · Malaria  ·  Sponsor: University of California, San Francisco

PhasePhase 3
Planned participants7530
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersYes

About this study

FLAME is an open-label cluster-randomized controlled trial that aims to determine the effectiveness of focal mass drug administration (fMDA) to reduce the incidence of Plasmodium vivax malaria in the Loreto Department in Peru. Standard interventions, including symptomatic and asymptomatic screening for malaria infections, provision of insecticide-treated bednets, and environmental transmission monitoring, will be compared to clusters of villages randomized to receive anti-malarial drugs.

This description comes directly from the study's public registry record.

Talk to the study team

Sydney Fine, MPH  ·  415-476-5494  ·  sydney.fine@ucsf.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Asociación Civil Selva AmazónicaIquitos, PeruRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05690841